Market Currents
Amgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it...
-
Tuesday, April 10, 2012, 8:52 AM ETAmgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it widespread rights for kidney disease treatment KAI-4169. As part of the agreement between the firms, Amgen has provided a loan to enable Phase 3 clinical development planning for KAI-4169 prior to the transaction closing.
Other date
Latest Articles
